Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study:A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with orwithout Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients withDefici